Type I carbohydrate-deficient glycoprotein syndrome (CDGS) patients fail to add entire N-linked oligosaccharide chains to some serum glycoproteins. Here we show that four CDGS fibroblast cell lines have two related glycosylation abnormalities. First, they incorporate 3-10-fold less 
Introduction
Carbohydrate-deficient glycoprotein syndromes (CDGS) 1 are autosomal recessive disorders that affect multiple organ systems (1, 2) . All patients show altered isoelectric focusing patterns of multiple serum glycoproteins that result from undersialylation of their N-linked oligosaccharides (3, 4) . The reduced sialylation in one patient with the rarer type II CDGS can be fully explained by the absence of Golgi enzyme GlcNAc transferase II (1, 5) . This enzyme is required to make sialylated biantennary N-linked oligosaccharides typical of many serum glycoproteins (6) . The undersialylation in the more common type I CDGS clearly results from the complete absence of one or more N-linked oligosaccharide chains on the proteins (7) (8) (9) (10) . The basis of this defect has been proposed to be in the biosynthesis of the lipid-linked oligosaccharide (LLO) precursor or its transfer to proteins (1, 7, 8) . However, CDGS fibroblasts appear to be normal in oligosaccharyl transferase and in UDP-GlcNAc:dolichol phosphate GlcNAc-1-P transferase, the first enzyme in LLO biosynthesis (11, 12) .
We recently reported that the carbohydrate content of total serum glycoproteins from two CDGS patients was reduced by ‫ف‬ 30%, but the monosaccharide composition and types of N-linked oligosaccharides were normal (13) . Metabolic labeling of two fibroblasts with [ 3 H]mannose showed a 2.5-5-fold decrease in the incorporation into both glycoproteins and LLO of CDGS cells compared with controls. We have now expanded this study to four CDGS patients and found that reduced protein glycosylation probably results from an inadequate supply of mannose needed for N-linked oligosaccharide biosynthesis, and not from a clear lesion in any step leading to protein glycosylation. Adding exogenous mannose to cells in culture corrects the biochemical lesions. control fibroblasts are from pediatric patients with lactic acidosis, fatty acid/glutaric disorders, and movement disorders, expressing normal transferrin patterns. Normal adult fibroblasts (CRL 1826) were obtained from American Type Culture Collection (Rockville, MD).
Cell lines were grown in ␣ -MEM containing 10% heat-inactivated FBS and 2 mM glutamine. When the long-term effect of mannose was studied, both normal and CDGS cells were grown for 10 d in the regular growth medium containing 1 mM d -mannose, and the medium was changed every day.
Determination S ]methionine (2 Ci/ml) for 60 min in DMEM containing 0.5 mM glucose and 2 mM glutamine. After removal of the radioactive medium, cells were quickly washed three times with ice-cold PBS and harvested by trypsinization, counted, sonicated, and solubilized in 0.1% SDS. The lysate was divided into four aliquots and used for protein determination and TCA precipitation before and after peptide: N -glycosidase F (PNGase F) or endoglycosidase H (Endo H) digestion. TCA-precipitated radiolabel was counted and normalized to protein content. PNGase F and Endo H digestions were done as described previously (14) .
Isolation H]mannose (100 Ci/ml) in DMEM containing 0.5 mM glucose and 2 mM glutamine (15). After removing the labeling medium, cells were quickly washed three times with ice-cold PBS to remove free label, and the plate was immediately flooded directly with 5 ml of chloroform/methanol (CHCl 3 /MeOH, 2:1 vol/vol) at 0 Њ C (15). Cells were scraped and stored at Ϫ 20 Њ C until processed. Cells were vortexed to disperse cell clumps and centrifuged at 3,000 rpm for 5 min. Pellets were extracted twice with 5 ml of the same solvent, and this combined extract (fraction I) was used to measure dolichol-P-mannose (dol-P-Man) content. The residual pellet after CHCl 3 / MeOH extraction was dried under a stream of nitrogen, suspended in 1 ml of water, sonicated, centrifuged, and washed three times with 5 ml of water. This combined water wash (fraction II) was used to measure labeled free oligosaccharides, mannose phosphates, and sugar nucleotides. The remaining cell pellet was extracted three times with 5 ml of CHCl 3 /MeOH/H 2 O (10:10:3 vol/vol) (fraction III) to isolate LLO. Oligosaccharides from the lipid were released by mild acid hydrolysis (15). The final cell pellet was solubilized in 0.1% SDS (fraction IV) and digested with PNGase F to release the proteinbound N-linked oligosaccharides (14), which were reduced with sodium borohydride in sodium borate buffer, pH 9.8, desalted, and analyzed by HPLC on an amine adsorption column with a linear gradient of acetonitrile (65-35%) in water as described previously (16) .
Measurement of dol-P-Man. CHCl 3 /MeOH extract (fraction I) was partitioned into CHCl 3/ MeOH/H 2 O (3:2:1 vol/vol). The organic phase was dried, hydrolyzed in 0.01 N HCl for 15 min at 100 Њ C, and again partitioned into CHCl 3/ MeOH/H 2 O (3:2:1 vol/vol). Radioactivity partitioning into the aqueous phase was taken as dol-P-Man content (17) . Authentic dol-P-Man was completely hydrolyzed under these conditions and partitioned into the aqueous phase. The quantitation of labeled dol-P-Man by this method was confirmed by thinlayer chromatography and by counting individual 0.5-cm sections.
Separation of water soluble components on Con A-Sepharose. The water-soluble material in fraction II was fractionated on Con A-Sepharose in microfuge spin filter baskets as described below. Material that did not bind to Con A was used for estimating the amount of mannose phosphates and sugar nucleotides. Con A-bound material was eluted with 100 mM ␣ -methyl mannoside ( ␣ -MeMan) and applied to a G-10 Sephadex column to remove ␣ -MeMan. The single radioactive peak near the void volume (Vo) was pooled, concentrated, and loaded on to QAE-Sephadex (in spin columns). The unbound neutral oligosaccharides were reduced and analyzed by HPLC as described above. Anionic oligosaccharides bound to QAE were eluted with 70 mM NaCl, desalted on Sephadex G-10, and concentrated. They were subsequently digested with alkaline phosphatase or treated with 0.1 N HCl for 10 min at 100 Њ C to remove the negative charge before reduction and HPLC analysis.
Spin columns. Samples in a volume of 50 l were applied to 200 l of Con A-Sepharose or QAE-Sephadex packed in spin columns and spun at 1,500 rpm in a microfuge tube for 1-2 min. Columns were washed four times with 200 l of water, and the bound material was eluted with 5 ϫ 200 l of preheated (60 Њ C) 100 mM ␣ -MeMan (for Con A-Sepharose) or 70 mM NaCl (for QAE).
Determination of [ 3 H]mannose phosphates and sugar nucleotides. The Con A-Sepharose unbound material is expected to contain 3 H-labeled mannose (Man), mannose-6-phosphate (Man-6-P), mannose-1-phosphate (Man-1-P), GDP-mannose (GDP-Man), and GDP-fucose (GDP-Fuc). We measured the amount of each of these components using a series of enzymatic reactions. All of the determinations are based on the ability of phosphomannose isomerase (PMI) to convert [ 3 H]Man-6-P into fructose-6-P with the release of 3 H 2 O (18, 19), which can be removed by evaporation. The amount of Man-6-P is measured by direct conversion to 3 H 2 O using PMI. Mannose is measured by converting it to Man-6-P with hexokinase. Man-1-P is converted to Man by alkaline phosphatase digestion, and then to Man-6-P with hexokinase. The remaining labeled material represents GDP-Man and GDP-Fuc. All reactions were carried out at 37 Њ C for 1 h in a volume of 50 l containing the sample, 50 mM Tris-HCl, pH 8.0, 6 mM MgCl 2 , and 1 mU of required enzymes, PMI, HK, or alkaline phosphatase (20, 21) . Measurements were done on a single sample in the order described above, or by separate treatments of the sample divided into three aliquots. The results of both methods were the same. Conditions for these determinations were first worked out on individual standards or in mixtures containing various proportions of each component. In all cases, the conversions were Ͼ 95%, and as little as 10% of any one product in the mixture could be accurately measured. A detailed description of the above method will be presented elsewhere ( Asano et al. (22) with some modifications. The preincubation in the absence of serum was omitted, and the labeling was done in DMEM. Nearly confluent monolayers of fibroblasts in 35-mm multiwell plates were incubated with [ 3 H]2-deoxyglucose (10 Ci/ml) in DMEM containing 2 mM glutamine for 15 min at 37 Њ C. Labeling was terminated by the addition of 2 ml of ice-cold PBS containing 10 mM glucose and 0.3 mM phloretin, and the cells were rapidly washed three times with icecold PBS containing glucose and subsequently solubilized with 0.1% SDS. Aliquots of these were assayed for radioactivity and protein.
Results

Lipid and protein-bound oligosaccharides in CDGS cells.
In previous studies, we found that two CDGS cell lines incorporated 2.5-5-fold less [ 3 H]mannose into LLO and protein compared with normal cells (13) . To extend these results, we analyzed the size of labeled oligosaccharides released from LLO or protein of controls and four CDGS cell lines. Normal cells make predominantly large LLO (Glc 1-3 Man 9 GlcNAc 2 ) ( Fig. 1) . Protein linked oligosaccharides released by PNGase F digestion had a size distribution similar to LLO, suggesting that little mannose processing occurs during labeling. This is supported by the finding that these oligosaccharides bind strongly to Con A-Sepharose and are not sialylated (not shown). In contrast, CDGS cells usually synthesize and transfer much smaller (Man 4-6 GlcNAc 2 ) oligosaccharides to proteins (Fig. 1) , and IV (protein) were isolated and processed as described in Methods. Sizes of the oligosaccharides were analyzed using an amine adsorption HPLC column that separates oligosaccharides according to size, with larger eluting later. 1-ml fractions were collected and counted for radioactivity. The shaded area in the water wash of control indicates the elution pattern of Con A-bound anionic oligosaccharides derived from fraction II after dephosphorylation with alkaline phosphatase. The elution position of the standards are indicated by arrows labeled with 5 (Man 5 GlcNAc 2 ) and 9 (Glc 1-3 Man 9 GlcNAc 2 ). come from glucose through a pathway involving PMI; (b) plasma mannose may be transported (Transporter) inside the cell; or (c) it may also be salvaged from LLO degradation and typical oligosaccharide processing (Turnover). The relative contribution of mannose from each of these sources is unknown. Mannose is converted into Man-6-P and then to Man-1-P, which is used to synthesize GDP-Man and dol-P-Man for LLO. INSIDE and OUTSIDE refer to the cell. ration into protein, we compared these parameters in normal, disease control, and CDGS cells at different passages. Cells of the same passage, from widely different passages or at different densities, were labeled on the same day with [ 3 H]mannose and digested with PNGase F and Endo H. Regardless of the passage number and cell density, normal and disease control cells always make primarily (80%) Endo H-sensitive oligosaccharides. In contrast, the proportion of Endo H-sensitive oligosaccharides varied from 10-80% in CDGS cells, and had a 3-10-fold decrease in [ 3 H]mannose incorporation. It appears that N-linked oligosaccharide synthesis in CDGS cells under these conditions is inherently variable. The control and CDGS cells grew at the same rate (with 60 h doubling time), and there were no obvious differences in the cell size, morphology, or protein content compared with the controls. Since fibroblasts from normal and each of three different disease control cells behaved the same in these experiments, we sometimes used only the disease control cells or normal cells in subsequent experiments.
Glycosylation in CDGS cells resembles glucose starvation. The combination of underglycosylation and truncated LLO size has been seen in cells during glucose starvation (24-32). These cells mostly synthesize Man 5 GlcNAc 2 and in some cases fully glucosylated LLO (Glc 3 Man 5 GlcNAc 2 ) (31, 32). There is a considerable cell-type variation in the degree of underglycosylation and time required to see the effects, but, in all cases, only the addition of either glucose or mannose corrects both of the glycosylation defects. Although the basis of the glucose starvation effect is unknown, the similar efficacy of glucose and mannose can be easily explained by the assumption that the bulk of Man-6-P used for glycoprotein synthesis is derived from glucose through a pathway involving PMI (Fig. 2) .
Based on this rationale, we considered the possibility that CDGS cells have insufficient intracellular glucose, perhaps induced by replacing the normal glucose (5.0 mM) medium with labeling medium that contains 0.5 mM glucose. This medium is commonly used to improve [ 3 H]Man labeling efficiency by reducing the mutual competition of mannose and glucose for the hexose transporters (18, 33) . To test this possibility, the glucose concentration was increased up to 5 mM during or 1 h before the labeling, but this did not have any effect on either underglycosylation or oligosaccharide size (Fig. 3) (Fig. 4) . Addition of mannose to CDGS cells corrected the LLO size to Glc 1-3 Man 9 GlcNAc 2 (Fig. 5) , and these normalsized chains were transferred to protein (data not shown). In- The incorporation into glycoprotein was measured by TCA precipitation, and the oligosaccharide size was measured by Endo H sensitivity as described in Methods. TCA precipitable counts were normalized to protein content and taken as the total incorporation into glycoproteins (glycosylation). The difference in the TCA precipitable counts before and after Endo H digestion represents the oligosaccharides with structure Ͼ Man 5 GlcNAc 2 (Endo H sensitive). Glycosylation (A) and Endo H sensitivity (B) in normal cells are taken as 100%, and those in CDGS patients are shown as a percentage of this value. creased mannose does not alter the size of the oligosaccharides made by normal cells. The effect of mannose on CDGS cells was seen even in the presence of 5 mM glucose (Fig. 6) , showing that the effect is exclusive for mannose under these conditions. l-Mannose is also ineffective, presumably since it cannot be transported and/or phosphorylated by hexokinase.
Effects of long-term incubation of mannose on cells. To determine whether prolonged incubation with mannose corrects the altered glycosylation, CDGS fibroblasts were grown in 1 mM d-mannose for up to 10 d before labeling. The exogenous mannose was removed and cells were labeled with only [ 3 H]mannose (1 M) in the presence of 0.5 mM glucose. Under these conditions, the amount of incorporation and Endo H sensitivity of the labeled oligosaccharides were the same as those of cells that had never been grown in mannose (data not shown). This finding supports the idea that mannose must be continually present to correct the underglycosylation and the truncated size of the oligosaccharides in CDGS fibroblasts.
Fractionation and analysis of [ 3 H]mannose-labeled products in control and CDGS lines.
The correction of abnormal glycosylation in CDGS cells by mannose suggested that there might be a specific deficiency in one or more of the intermediates leading to LLO. To search for a specific deficiency, we analyzed a broad range of [ Fraction I. The majority of labeled material in fraction I is dol-P-Man, and the amount is similar in CDGS cells and the control. This was surprising in view of the reduction in the amount of label in all of the other fractions analyzed.
Fraction II, Con A-bound material. The amount of label in fraction II is also 3-10-fold lower in CDGS cells than in the control. This fraction should contain 3 H-labeled Man and metabolic intermediates Man-6-P, Man-1-P, GDP-Man, and GDPFuc, but ‫ف‬ 35-60% of the label in fraction II from each cell line bound to Con A-Sepharose. This material is composed of free oligosaccharides rather than glycopeptides, since it did not bind to cation exchange resin (Dowex-50). The size of these oligosaccharides also closely resembles that of those derived from protein-bound oligosaccharides (shown in Fig. 1 ), and they are most likely cleaved from protein or LLO as reported by others (34) (35) (36) (37) (38) (39) (40) .
About 15-40% of the Con A-Sepharose-bound material also binds to QAE-Sephadex and is eluted by 70 mM NaCl, suggesting that this material contains two negative charges (41) . Alkaline phosphatase digestion, or mild acid hydrolysis (0.1 N HCl, 10 min, 100ЊC) eliminates binding to the resin. These molecules probably have a phosphomonoester on the reducing GlcNAc and were derived from LLO by pyrophosphatase-type cleavage. The alkaline phosphatase-neutralized oligosaccharides from the control are small (Man 5 GlcNAc 2 -size; Fig. 1, top right panel, shaded area) , and not typical of the entire LLO pattern. This shows that selected LLOs are preferentially hydrolyzed in control cells. In CDGS, the size of the anionic oligosaccharides is also small, and, in this case, they reflect the truncated LLO pattern (data not shown).
The amount of Con A-Sepharose-bound material differs in each cell line (Table III) , but it is nearly the same proportion of the total H-labeled Man, Man-6-P, Man-1-P, and GDP-Man ϩ GDP-Fuc in fraction II were determined as described in Methods (Table III) ]mannose incorporation into LLO precursors fractions. To determine whether increased exogenous mannose normalized the incorporation into various fractions, normal and two CDGS cell lines were labeled in the absence and presence of 1 mM exogenous d-mannose, and the products were analyzed as before (Table  IV) . In this experiment the amount of dol-P-Man is 1.5-2-fold less than in normal cells. This was in contrast to four previous experiments where CDGS and normals had the same amount of dol-P-Man. All the other fractions (II-IV) had 2-20-fold less label than the normal, and addition of mannose produces normal levels. These results support the idea that CDGS fibroblasts are limited in the availability of mannose inside the cell for N-linked protein glycosylation.
Discussion
Type I CDGS patients show reduced N-linked glycosylation of many proteins (1) . In previous studies, fibroblasts from two CDGS patients incorporated less [ 3 H]mannose into both glycoproteins and LLO compared with controls (13) . Based on these results, we suggested that there was a deficiency in the synthesis of LLO. Another possibility is that the LLO is rapidly degraded, but this is ruled out by the finding that the proportion of free oligosaccharides is nearly the same in CDGS and controls. We also found that cells from CDGS patients usually make smaller LLO species (Man [4] [5] [6] (46) . In some of our experiments, CDGS cells made mostly normal-sized LLO, showing that the defect in CDGS is not in one of the LLO mannosyl transferases. We also found that CDGS cells usually synthesize a normal amount of dol-P-Man, suggesting that the defect in CDGS is not the same as in Thy E cells that invariably synthesize a specific LLO (Glc 3 Man 5 GlcNAc 2 ) due to dol-P-Man synthase deficiency (47) .
Similar aberrant LLO synthesis and underglycosylation are seen in cultured cells during glucose starvation (24-32). This well-documented but unexplained phenomenon shows considerable cell-type variation. Normal glycosylation is restored by the addition of 50 M of either glucose or mannose but not by any other sugars or by pyruvate and glutamine (24-27). In baby hamster kidney cells, galactose also partially reverses the starvation effects (25) . Glucose-starved Chinese hamster ovary cells also show a drastic reduction in dol-P-Man, and in this way they resemble dol-P-Man synthase deficiency seen in Thy E cells (31, 47) . More recently, similar effects of glucose limitation have been seen in the underglycosylation of recombinant proteins (48-51). Although the physiological basis of this phenomenon remains unknown, the weight of the evidence seems to point to a deficiency in obtaining or generating mannose for glycoprotein synthesis. Based on the similarity to the glucose starvation effect, it was surprising that mannose, but not glucose, corrects the altered glycosylation in CDGS cells, since the bulk of endogenous mannose for glycoprotein synthesis is assumed to be derived from glucose through PMI (Fig. 2) . However, we have already shown that this enzyme and others involved in this pathway (hexokinase and phosphoglucose isomerase) appear to be normal in CDGS cells (21) . This may mean that glucose is not actually the predominant source of mannose for glycoprotein synthesis and that adding mannose to CDGS cells bypasses the deficiency from the other pathway(s). In this regard, it is important to note that the quantitative contribution of glucose-derived mannose in mammalian glycoprotein synthesis has not actually been established. Cells may acquire mannose in other ways (Fig. 2) . One possible source is from the plasma, which contains ‫ف‬ 30-50 M mannose (52) . Another is from the degradation of pinocytosed serum glycoproteins or from the turnover of endogenous glycoproteins and oligosaccharides. Mannose released from LLO degradation and oligosaccharide "trimming" alone could total 80% of the mannose initially incorporated into LLO. Mammalian cells are equipped with an array of ␣-mannosidases to degrade many linkages and generate free mannose (53) . The absence of solid results on the origin of mannose in higher organisms is further complicated by untested assumptions and extrapolations from other systems. For instance, although PMI is ubiquitous, the effects of a gene deletion have not been tested in mammalian cells. Loss of PMI in yeast is lethal (54) , but the much larger metabolic load and 100-fold higher specific activity in yeast than in mammalian cells may make such a comparison unwarranted.
Since glucose and mannose can be carried by the same hexose transporter, a possible explanation for decreased mannose labeling in CDGS is a defective glucose transporter. This is unlikely since CDGS fibroblasts were only slightly less efficient in [ We found that CDGS cells also had considerably less 3 H-labeled intermediates, GDP-Man ϩ GDP-Fuc, Man-1-P, Man-6-P, and Man, compared with controls, and these decreases corresponded well to the lowered amount of LLO and protein-bound oligosaccharides. The exception to this pattern is dol-P-Man, which seems to be much closer to normal in CDGS cells. The reasons for this are unknown, but dol-P-Man synthase may preferentially use GDP-Man because of a lower K m , or dol-P-Man may accumulate because of lack of utilization in making larger LLOs. Alternatively, dol-P-Man might use a separate pool of GDP-Man from that used in the other reactions. Could the glycosylation abnormalities as measured by [ 3 H]mannose labeling be explained simply by changes in the size of the precursor pools or in the specific activities of labeled products? We think this is unlikely since [ H-labeled intermediates except dol-P-Man decreased in the same proportion and were similar to decreases in LLO and protein-linked oligosaccharides, it appears that CDGS cells metabolize mannose normally. Because glucose could not correct both defects, it is tempting to speculate that CDGS cells may be defective in generating mannose from both exogenous and endogenous sources (Fig. 2) . The defect in type I CDGS has been mapped to a region on chromosome 16p (56), but it is not clear how a single mutation can account for underutilization of both endogenous and exogenous sources of mannose. Regardless of the source of mannose for glycoprotein synthesis, it is clear that mannose can correct the defects in CDGS fibroblasts. This leads to the intriguing possibility that patients may benefit from an ongoing dietary supplement of mannose or mannose-containing foods. Although very few studies have been done on mannose metabolism in mammals, in moderate doses, mannose should be nontoxic (57) . More basic physiological analysis will be required before we can assess the potential benefits of mannose for CDGS patients. 
Note added in proof:
A recent report (van Shaftingen, E., and J. Jaeken, 1996 . FEBS Lett. 377:318-320) showed that four Type I CDGS patients were ‫ف‬ 95% deficient in phosphomannomutase. The authors concluded that this deficiency is probably the major cause of the disorder. However, their results do not explain how mannose corrects the altered glycosylation in the patients we studied. It remains to be seen whether there are other causes of Type I CDGS.
